Genus Oncology has dosed the first patient in a Phase I trial to evaluate its GO-203-2c compound as a treatment for solid tumours.
The prospective, open-label trial is designed to determine the safety, tolerability and potential anti-tumour activity of GO-203-2c.
Go deeper with GlobalData
Up to 40 patients will be enrolled at multiple clinical sites.
GO-203-2c is the optimised lead peptide drug candidate, synthesised to target MUC1, an oncoprotein that is over-expressed in many human carcinomas.
Genus has also filed an investigational new drug application with the US Food & Drug Administration.
GlobalData Strategic Intelligence
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
